US6211348B1 - Hydroxy derivatives of tylosin and process for their preparation - Google Patents

Hydroxy derivatives of tylosin and process for their preparation Download PDF

Info

Publication number
US6211348B1
US6211348B1 US09/393,322 US39332299A US6211348B1 US 6211348 B1 US6211348 B1 US 6211348B1 US 39332299 A US39332299 A US 39332299A US 6211348 B1 US6211348 B1 US 6211348B1
Authority
US
United States
Prior art keywords
double bond
och
line
noh
mycarosyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US09/393,322
Inventor
Amalija Narandja
Nevenka Lopotar
Zoran Mandić
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fidelta doo
Original Assignee
Pliva Farmaceutska Industrija dd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pliva Farmaceutska Industrija dd filed Critical Pliva Farmaceutska Industrija dd
Assigned to PLIVA, FARMACEUTSKA INDUSTRIJA, DIONICKO DRUSTVO reassignment PLIVA, FARMACEUTSKA INDUSTRIJA, DIONICKO DRUSTVO ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LOPOTAR, NEVENKA, MANDIC, ZORAN, NARANDJA, AMALIJA
Application granted granted Critical
Publication of US6211348B1 publication Critical patent/US6211348B1/en
Assigned to PLIVA-ISTRAZIVACKI INSTITUT D.O.O. reassignment PLIVA-ISTRAZIVACKI INSTITUT D.O.O. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PLIVA D.D.
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Definitions

  • the present invention relates to tylosin derivatives, new synthetic products of the macrolide class exhibiting antimicrobial activity. It particularly relates to 12,13-dihydroxy tylosin derivatives of the formula (I)
  • R represents O, R 1 represents CHO, CH ⁇ NOH or CH(OCH 3 ) 2 , R 2 represents H or mycarosyl, R 3 represents N(CH 3 ) 2 or NO(CH 3 ) 2 , and - - - line represents a single or a double bond, with the proviso that R 3 represents N(CH 3 ) 2 when - - - line represents a single bond;
  • R represents NOH
  • R 1 represents CHO or CH(OCH 3 ) 2
  • R 2 represents H or mycarosyl
  • R 3 represents N(CH 3 ) 2 or NO(CH 3 ) 2 , and - - - line represents a single or a double bond, with the proviso that R 3 represents N(CH 3 ) 2 when - - - line represents a single bond;
  • R represents O, R 1 represents CHO, CH ⁇ NOH or CH(OCH 3 ) 2 , R 2 represents H or mycarosyl, R 3 represents N(CH 3 ) 2 or NO(CH 3 ) 2 , and - - - line represents a single or a double bond, with the proviso that R 3 represents N(CH 3 ) 2 when - - - line represents a single bond;
  • R represents NOH
  • R 1 represents CHO or CH(OCH 3 ) 2
  • R 2 represents H or mycarosyl
  • R 3 represents N(CH 3 ) 2 or NO(CH 3 ) 2 , and - - - line represents a single or a double bond, with the proviso that R 3 represents N(CH 3 ) 2 when - - - line represents a single bond;
  • R represents H or mycarosyl, dissolved in a halogenated hydrocarbon, preferably in methylene chloride, to an oxidation reaction with 3 to 8 equivalents of m-chloroperbenzoic acid within 6 to 20 hours at room temperature, whereupon, optionally,
  • R represents O
  • R 1 represents CH(OCH 3 ) 2
  • R 2 represents H or mycarosyl
  • R 3 represents NO(CH 3 ) 2
  • - - - line represents a double bond
  • a compound of formula (I), wherein R represents NOH, R 1 represents CH(OCH 3 ) 2 , R 2 represents H or mycarosyl, R 3 represents NO(CH 3 ) 2 , and - - - line represents a double bond, is subjected to the reduction of N-oxide according to process A, or optionally, to the reduction of N-oxide and the double bond by the catalytic hydrogenation as described under B1,
  • novel compounds are isolated by conventional extraction processes from aqueous alkaline solutions by the use of halogenated hydrocarbons such as methylene chloride, chloroform or tetrachloromethane, and by evaporation to a dry residue.
  • halogenated hydrocarbons such as methylene chloride, chloroform or tetrachloromethane
  • reaction course is followed by chromatography on thin layer of silica gel (Merck 60 F 254 ) in a solvent system: methylene chloride-methanol-ammonium hydroxide 25% (90:9:1.5, system E), (90:9:0.5, system E1) or chloroform-methanol-ammonium hydroxide 25% (95:15:1.5, system AJ).
  • solvent system methylene chloride-methanol-ammonium hydroxide 25% (90:9:1.5, system E), (90:9:0.5, system E1) or chloroform-methanol-ammonium hydroxide 25% (95:15:1.5, system AJ).
  • silica gel column Merck 60, 230-400 mesh/ASTM, or 60-230 mesh/ASTM in solvent system E, E1 or AJ.
  • the identification of the novel compounds is performed by UV and NMR spectroscopies and by mass analysis.
  • novel compounds show antibacterial activity, but can also be used as intermediates for the preparation of new derivatives.
  • the Hg-basin was used as a working electrode (cathode), whereas graphite was used as a counter electrode and a saturated calomel electrode was used as a reference electrode.
  • the reaction was performed under a constant potential of ⁇ 1.4 V towards the saturated calomel electrode at room temperature within 40 minutes at a charge waste of 80 C.
  • the reaction solution was alkalized to a pH-value of 8.5 and extracted with chloroform.
  • the extract was washed with a saturated NaHCO 3 solution and evaporated to a dry residue.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Seasonings (AREA)
  • Steroid Compounds (AREA)

Abstract

The present invention relates to 12,13-dihydroxy derivatives of tylosin, new semisynthetic compounds of the macrolide class, and to a process for their preparation. According to the present invention by the oxidation of 13-hydroxy derivative a 12,13-dihydroxy compound is obtained, which can be subsequently subjected to a series of reactions such as oximation, reduction (catalytic, electrochemical) or hydrolysis yielding corresponding dihydro or tetrahydro 12,13-dihydroxy derivatives.

Description

TECHNICAL FIELD
International Patent Classification: A 61 K 31/70, C 07 H 17/08
TECHNICAL PROBLEM
The present invention relates to tylosin derivatives, new synthetic products of the macrolide class exhibiting antimicrobial activity. It particularly relates to 12,13-dihydroxy tylosin derivatives of the formula (I)
Figure US06211348-20010403-C00001
wherein
R represents O, R1 represents CHO, CH═NOH or CH(OCH3)2, R2 represents H or mycarosyl, R3 represents N(CH3)2 or NO(CH3)2, and - - - line represents a single or a double bond, with the proviso that R3 represents N(CH3)2 when - - - line represents a single bond;
wherein
R represents NOH, R1 represents CHO or CH(OCH3)2, R2 represents H or mycarosyl,
R3 represents N(CH3)2 or NO(CH3)2, and - - - line represents a single or a double bond, with the proviso that R3 represents N(CH3)2 when - - - line represents a single bond;
and to a process for their preparation.
PRIOR ART
It is known that 13-hydroxy derivatives of tylosin have been prepared by the reductive opening of the oxirane ring of 12,13-epoxy tylosin derivative, followed by catalytic hydrogenation, oximation or hydrolysis reactions (A.Narandja, SI 9700281).
According to the known prior art, the introduction of a second hydroxyl group and the formation of a vicinal diol have not been described as yet, therefore 12,13-dihydroxy derivatives of tylosin represent novel, hitherto not described compounds, which is also true of processes for their preparation.
TECHNICAL SOLUTION
It has been found that 12,13-dihydroxy tylosin derivatives of the formula
Figure US06211348-20010403-C00002
wherein
R represents O, R1 represents CHO, CH═NOH or CH(OCH3)2, R2 represents H or mycarosyl, R3 represents N(CH3)2 or NO(CH3)2, and - - - line represents a single or a double bond, with the proviso that R3 represents N(CH3)2 when - - - line represents a single bond;
wherein
R represents NOH, R1 represents CHO or CH(OCH3)2, R2 represents H or mycarosyl,
R3 represents N(CH3)2 or NO(CH3)2, and - - - line represents a single or a double bond, with the proviso that R3 represents N(CH3)2 when - - - line represents a single bond;
can be prepared by subjecting a compound of the formula (II)
Figure US06211348-20010403-C00003
wherein R represents H or mycarosyl, dissolved in a halogenated hydrocarbon, preferably in methylene chloride, to an oxidation reaction with 3 to 8 equivalents of m-chloroperbenzoic acid within 6 to 20 hours at room temperature, whereupon, optionally,
a compound of formula I, wherein
R represents O, R1 represents CH(OCH3)2, R2 represents H or mycarosyl, R3 represents NO(CH3)2, and - - - line represents a double bond, is subjected:
A/ to a reduction of N-oxide with Zn-powder in a mixture of lower C1-C3-aliphatic alcohol and water under the addition of 3-5% w/v of ammonium chloride at a pH value of 2 to 7, preferably in the range of 5.0 to 5.5 at room temperature within 3 to 6 hours,
or optionally
B/ to a reduction of N-oxide and C10-C11double bond
B1/ by a catalytic hydrogenation process in an organic solvent, preferably in a lower C1-C3 aliphatic alcohol in the presence of 2 to 5% w/w palladium on charcoal at a hydrogen pressure of 0.2 to 0.5 MPa at room temperature within 5 to 8 hours;
or optionally
B2/ by an electrochemical reduction process in an electrochemical cell with separate anode and cathode compartments, wherein there are used a Hg-basin as a working electrode (cathode), graphite as a counter electrode and a saturated calomel electrode as a reference electrode, in a phosphate buffer (pH=5.4) at a constant potential of −1.4 V towards the saturated calomel electrode at room temperature within 40 minutes and a charge waste of 80 C;
or optionally,
C/ to an oximation reaction with 1 to 8 equivalents of hydroxylamine hydrochloride in pyridine or a lower C1-C3aliphatic alcohol under the addition of a base (pyridine or Na2CO3) in a nitrogen stream at room temperature or reflux temperature within 1 to 10 hours,
or optionally,
a compound of formula (I), wherein R represents NOH, R1 represents CH(OCH3)2, R2 represents H or mycarosyl, R3 represents NO(CH3)2, and - - - line represents a double bond, is subjected to the reduction of N-oxide according to process A, or optionally, to the reduction of N-oxide and the double bond by the catalytic hydrogenation as described under B1,
or optionally,
a compound of the formula (I), wherein R represents O, R1 represents CH(OCH3)2, R2 represents H or mycarosyl, R3 represents N(CH3)2, and - - - line represents a single or a double bond, is subjected to the oximation reaction as described under C,
or optionally,
a compound of formula (I), wherein R represents NOH, R1 represents CH(OCH3)2, R2 represents H or mycarosyl, R3 represents N(CH3)2, and - - - line represents a single or a double bond, is subjected to hydrolysis in a mixture of acetonitrile and 0.2 N HCl (2:1) or of acetonitrile and 1% aqueous solution of trifluoroacetic acid (1:2) at room temperature within 2 hours,
or optionally,
a compound of formula (I), wherein R represents O, R1 represents CHO, R2 represents H or mycarosyl, R3 represents N(CH3)2, and - - - line represents a single or a double bond, is subjected to the oximation reaction as described under C.
According to the present invention the novel compounds are isolated by conventional extraction processes from aqueous alkaline solutions by the use of halogenated hydrocarbons such as methylene chloride, chloroform or tetrachloromethane, and by evaporation to a dry residue.
The reaction course is followed by chromatography on thin layer of silica gel (Merck 60 F254) in a solvent system: methylene chloride-methanol-ammonium hydroxide 25% (90:9:1.5, system E), (90:9:0.5, system E1) or chloroform-methanol-ammonium hydroxide 25% (95:15:1.5, system AJ). If appropriate, the separation of the reaction products and the purification of the products for the purpose of spectral analyses are performed on a silica gel column (Merck 60, 230-400 mesh/ASTM, or 60-230 mesh/ASTM in solvent system E, E1 or AJ). The identification of the novel compounds is performed by UV and NMR spectroscopies and by mass analysis.
The novel compounds show antibacterial activity, but can also be used as intermediates for the preparation of new derivatives.
The present invention is illustrated but in no way limited by the following Examples.
EXAMPLE 1 12,13-dihydro-12,13-dihydroxy-desmycosin(3′N-oxide) 20-dimethyl acetal (1)
10,13-dihydro-13-hydroxy-desmycosin 20-dimethyl acetal (10 g, 12 mmole) was dissolved in methylene chloride (150 ml), m-chloroperbenzoic acid 71% (11.6 g, 48 mmole) was added and it was stirred at room temperature for 8 hours. The reaction solution was poured into 400 ml of water, alkalized to a pH value of 8.5 by the addition of 20% NaOH, stirred for 30 minutes and, subsequently, after the removal of the organic layer, extracted once more by a mixture of methylene chloride and i-propanol (5:1). The combined extracts were washed with a saturated NaHCO3 solution, dried and evaporated to a dry residue. The crude product (6.92 g) was purified by chromatography on a column (system E).
Obtained: 4.5 g (43.3%) Rf(E) 0.35, MH+868; UV (EtOH) λmax 230 nm, log ε 3.88; 1H-NMR (CDCl3) δ ppm 6.84 (1H, d, H-11), 6.41 (1H, d, H-10), 4.52 (1H, d, 1′″), 4.50 (1H, m, H-20), 4.34 (1H, d, 1), 3.60 (3H, s, 3′″OMe), 3.44 (6H, s, N-Me, 2′″OMe), 3.34 (3H, s, 20-OMe), 3.29 (3H, s, 20-OMe), 3.25 (3H, s, N-Me); 13C-NMR (CDCl3) δ ppm 204.4 (s, C-9), 172.2 (s, C-1), 148.7 (d, C-11), 127.9 (d, C-10), 104.6 (d, C-1′, C-20), 99.7 (d, C-1′″), 76.2 (s, C-12), 75.4 (d, C-13), 61.3 (q, 3′″OMe, N-Me), 57.4 (q, 2′″OMe), 54.0 (q, 20-OMe, NMe), 51.8 (q, 20 OMe).
EXAMPLE 2 12,13-dihydro-12,13-dihydroxy-desmycosin(3′N-oxide)-9(E+Z)oxime 20-dimethyl acetal (2)
Compound 1 (3 g, 3.45 mmole) was dissolved in dry pyridine (25 ml), hydroxylamine hydrochloride (1.92 g, 27.6 mmole) was added and it was stirred in a nitrogen stream for 5 hours at room temperature. The reaction mixture was poured into 150 ml of water, alkalized to a pH-value of 9, whereupon pyridine was removed by azeotropic distillation. An extraction with a mixture of CHCl3 and i-PrOH (5:1) was performed and the combined extracts were dried and evaporated to a dry residue. The crude product (2.45 g) was subjected to chromatography on a silica gel column (system AJ).
Obtained: 0.58 g (51.7%) Rf(E1) 0.28, MH+883; UV (EtOH) λmax 230 rnm, log ε 3.71; 1H-NMR (DMSO-d6) δ ppm 10.79, 10.37 (1H, s, 9-NOH), disappear by agitation with D2O; 1H-NMR (CDCl3) δ ppm 6.25 (1H, d, H-11), 6.11 (1H, d, H-10), 4.52 (1H, d, 1′″), 4.50 (1H, m, H-20), 4.33 (1H, d, 1′), 3.61 (3H, s, 3′″OMe), 3.45 (6H, s, N-Me, 2′″OMe), 3.36 (3H, s, 20-OMe), 3.32 (3H, s, 20-OMe), 3.26 (3H, s, N-Me); 13C-NMR (CDCl3) δ ppm 171.8, 170.9 (s, C-1), 163.8, 159.0 (s, C-9), 143.2, 142.2 (d, C-11), 123.3, 115.3 (d, C-10), 104.7 (d, C-1′, C-20), 99.6 (d, C-1′″), 76.6 (s, C-12), 75.7 (d, C-13), 61.3 (q, 3′″OMe, N-Me), 57.4 (q, 2′″OMe), 54.0 (q, 20-OMe, NMe), 51.8 (q, 20-OMe).
EXAMPLE 3 12,13-dihydro-12,13-dihydroxy-tylosin (3′N-oxide) 20-dimethyl acetal (3)
10,13-dihydro-13-hydroxy-tylosin 20-dimethyl acetal (2.0 g, 2 mmole) was dissolved in methylene chloride (30 ml), m-chloroperbenzoic acid 71% (2.18 g, 9 mmole) was added and it was stirred at room temperature for 8 hours, whereupon the isolation as described in Example 1 was performed.
Obtained: 0.67 g (33%/) Rf(E1) 0.55, MH+1012; UV (EtOH) λmax 230 nm, log ε 3.58; 1H-NMR (CDCl3) δ ppm 6.82 (1H, d, H-11), 6.39 (1H, d, H-10), 5.08 (1H, d, 1″), 4.55 (1H, d, 1′″, 4.50 (1H, m, H-20), 4.34 (1H, d, 1′), 3.60 (3H, s, 3′″OMe), 3.44 (6H, s, NMe, 2′″OMe), 3.34 (3H, s, 20-OMe), 3.29 (3H, s, 20-OMe), 3.25 (3H, s, N-Me); 13C-NMR (CDCl3) δ ppm 203.6 (s, C-9), 172.2 (s, C-1) 148.7 (d, C-11), 127.9 (d, C-10), 104.6 (d, C-1′, C-20), 99.7 (d, C-1′″), 97.1 (d, C-1″), 61.3 (q, 3′″OMe, N-Me), 57.4 (q, 2′″OMe), 54.0 (q, 20-OMe, NMe), 51.8 (q, 20-OMe).
EXAMPLE 4 12,13-dihydro-12,13-dihydroxy-desmycosin 20-dimethyl acetal (4)
Compound 1 (1 g, 1.15 mmole) was dissolved in 35% ethanol (60 ml), 3.1 g of NH4Cl and stepwise 1 g of Zn under maintaining the pH-value of 5.0-5.5 were added. It was stirred at room temperature for 5 hours, whereupon Zn was separated by filtration and EtOH was removed by evaporation at reduced pressure. The aqueous solution was alkalized to a pH-value of 8.5, whereupon extraction with chloroform was performed. The extracts were dried and evaporated to a dry residue.
Obtained: 0.83 g (84.6%) Rf(E) 0.48, Rf (E1) 0.43, MH+852; UV (EtOH) λmax 230 nm, log ε 3.91; 1H-NMR (CDCl3) δ ppm 6.83 (1H, d, H-11), 6.39 (1H, d, H-10), 4.51 (1H, d, 1′″), 4.49 (1H, m, H-20), 4.35 (1H, d, 1′), 3.60 (3H, s, 3′″OMe), 3.44 (3H, s, 2′″OMe), 3.34 (3H, s, 20-OMe), 3.29 (3H, s, 20-OMe), 2.50 (6H, s, NMe2)3; 13C-NMR (CDCl3) δ ppm 204.5 (s, C-9), 172.3 (s, C-1) 148.9 (d, C-11), 127.9 (d, C-10), 104.6 (d, C-1′, C-20), 99.8 (d, C-1′″), 76.4 (s, C-12), 75.4 (d, C-13), 61.3 (q, 3′″OMe), 57.4 (q, 2′″OMe, 54.0 (q, 20-OMe), 51.8 (q, 20-OMe), 40.1 (q, NMe2).
EXAMPLE 5 12,13-dihydroxy-10,11,12,13-tetrahydroy-desmycosin 20-dimethyl acetal (5)
Process A
Compound 1 (1 g, 1.15 mmole) was dissolved in ethanol (50 ml), 0.5 g of 10% Pd/C were added and it was hydrogenated for 8 hours at a hydrogen pressure of 0.5 MPa at room temperature, whereupon the catalyst was separated by filtration and ethanol was evaporated to a dry residue.
Obtained: 0.88 g (90%/o) Rf(E) 0.45, MH+854; does not absorb in UV; 1H-NMR (CDCl3) δ ppm 4.55 (1H, d, 1′″), 4.52 (1H, m, H-20), 4.35 (1H, d, 1′), 3.60 (3H, s, 3′″OMe), 3.44 (3H, s, 2′″OMe), 3.34 (3H, s, 20-OMe), 3.29 (3H, s, 20-OMe), 2.50 (6H, s, NMe2); 13C-NMR (CDCl3) δ ppm 212.4 (s, C-9), 173.0 (s, C-1) 104.6 (d, C-1′, C-20), 99.7 (d, C1′″), 61.3 (q, 3′″OMe), 57.4 (q, 2′″OMe), 54.0 (q, 20-OMe), 51.8 (q, 20-OMe), 40.1 (q, NMe2).
Process B
Compound 1 (0.2 g, 0.23 mmole) was dissolved in 50 ml of phosphate buffer (pH=5.4) and then it was transferred into an electrochemical cell having separate anode and cathode compartments. The Hg-basin was used as a working electrode (cathode), whereas graphite was used as a counter electrode and a saturated calomel electrode was used as a reference electrode. The reaction was performed under a constant potential of −1.4 V towards the saturated calomel electrode at room temperature within 40 minutes at a charge waste of 80 C. The reaction solution was alkalized to a pH-value of 8.5 and extracted with chloroform. The extract was washed with a saturated NaHCO3 solution and evaporated to a dry residue.
Obtained: 0.16 g (81.6%) Rf(E) 0.45, Rf(E1) 0.43, MH+854 and the spectral characteristics as in the compound obtained by process 5A.
EXAMPLE 6 12,13-dihydroxy-10,11,12,13-tetrahydro-desmycosin-9(E+Z) oxime 20-dimethyl acetal (6)
Compound 2 (1 g, 1.13 mmole) was dissolved in ethanol (50 ml), 0.5 g of 10% Pd/C were added and it was hydrogenated for 9 hours at a hydrogen pressure of 0.5 MPa at room temperature, whereupon the catalyst was separated by filtration and ethanol was evaporated to a dry residue.
Obtained: 0.85 g (88%) Rf(E1) 0.43, MH+869; does not absorb in UV; 1H-NMR (DMSO-d6) δ ppm 10.69, 10.49 (1H, s, 9-NOH), dissapear by agitation with D2O; 1H-NMR (CDCl3) δ ppm 4.51 (1H, d, 1′″), 4.50 (1H, m, H-20), 4.32 (1H, d, 1′), 3.61 (3H, s, 3′″OMe), 3.45 (3H, s, 2′″OMe), 3.36 (3H, s, 20-OMe), 3.32 (3H, s, 20-OMe), 2.51 (6H, s, NMe2); 13C-NMR (CDCl3) δ ppm 172.5 (s, C-1), 165.6, 162.3 (s, C-9), 104.7 (d, C-1′), 104.5 (d, C-20), 99.6 (d, C-1′″), 61.3 (q, 3′″OMe), 57.4 (q, 2′″OMe), 54.0 (q, 20-OMe), 51.8 (q, 20-OMe).
EXAMPLE 7 12,13-dihydro-12,13-dihydroxy-desmycosin-9(E+Z) oxime 20-dimethyl acetal (7)
Compound 4 (2 g, 2.34 mmole) was dissolved in dry pyridine (25 ml), hydroxylamine hydrochloride (1.9 g, 27.6 mmole) was added and it was stirred in a nitrogen stream for 6 hours at room temperature. The isolation was performed as described in Example 2.
Obtained: 1.14 g (55.9%) Rf(E1) 0.39, MH+867; UV (EtOH) λmax 231 nm, log ε 3.97; 1H-NMR (DMSO-d6) δ ppm 10.77, 10.49 (1H, s, 9-NOH), dissapear by agitation with D2O; 1H-NMR (CDCl3) δ ppm 6.23 (1H, d, H-11), 6.09 (1H, d, H-10), 4.52 (1H, d, 1′″), 4.50 (1H, m, H-20), 4.33 (1H, d, 1′), 3.61 (3H, s, 3′″OMe), 3.45 (3H, s, 2′″OMe), 3.36 (3H, s, 20-OMe), 3.32 (3H, s, 20-OMe), 2.50 (6H, s, NMe2); 13C-NMR (CDCl3) δ ppm 171.9 (s, C-1), 163.6, 159.2 (s, C-9), 148.7, 143.8 (d, C-11), 123.6, 116.0 (d, C-10), 104.7 (d, C-1′, C-20), 99.6 (d, C-1′″), 76.6 (s, C-12), 75.5 (d, C-13), 61.3 (q, 3′″-OMe), 57.4 (q, 2′″OMe), 54.0 (q, 20-OMe), 51.8 (q, 20-OMe), 40.3 (q, NMe2).
EXAMPLE 8 12,13-dihydro-12,13-dihydroxy-desmycosin-9(E+Z) oxime (8)
Compound 7 (0.5 g, 0.58 mmole) was dissolved in acetonitrile (5 ml) and in 1% aqueous trifluoroacetic acid solution (10 ml) and it was stirred at room temperature for 2 hours. To the reaction mixture chloroform (8 ml) was added and it was alkalized to a pH-value of 8.5. One more extraction with chloroform was performed. The combined extracts were washed with 1% NaHCO3 solution, dried and evaporated to a dry residue.
Obtained: 0.4 g (85%) Rf (E1) 0.30, MH+821; UV (EtOH) λmax 232 nm, log ε 3.47; 1H-NMR (DMSO-d6) δ ppm 10.75, 10.48 (1H, s, 9-NOH), dissapear by agitation with D2O; 1H-NMR (CDCl3) δ ppm 9.67 (1H, s, H-20), 6.24 (1H, d, H-11), 6.10 (1H, d, H-10), 4.52 (1H, d, 1′″), 4.33 (1H, d, 1′), 3.61 (3H, s, 3′″OMe), 3.45 (3H, s, 2′″OMe), 2.50 (6H, s, NMe2); 13(C-NMR (CDCl3) δ ppm 203.1 (d, C-20), 172.9 (s, C-1), 163.2, 159.6 (s, C-9), 148.7 (d, C-11), 123.8, 115.9 (d, C-10), 104.7 (d, C-1′), 99.6 (d, C-1′″), 61.3 (q, 3′″OMe), 57.4 (q, 2′″OMe), 40.3 (q, NMe2).
EXAMPLE 9 12,13-dihydro-12,13-dihydroxy-desmycosin (9)
Compound 4 (1 g, 1.17 mmole) was dissolved in acetonitrile (10 ml) and in 1% aqueous trifluoroacetic acid solution (18 ml) and then hydrolysis and isolation were performed as in Example 8.
Obtained: 0.75 g (80%) Rf(E) 0.42, MH+806; UV (EtOH) λmax 230 nm, log ε 3.79; 1H-NMR (CDCl3) δ ppm 9.68 (1H, s, H-20), 6.81 (1H, d, H-11), 6.39 (1H, d, H-10), 4.52 (1H, d, 1′″), 4.33 (1H, d, 1′), 3.61 (3H, s, 3′″OMe), 3.45 (3H, s, 2′″OMe), 2.50 (6H, s, NMe2); 13C-NMR (CDCl3) δ ppm 203.2 (s, C-9), 203.1 (d, C-20), 172.9 (s, C-1), 148.7 (d, C-11), 124.0 (d, C-10), 104.7 (d, C-1′), 99.6 (d, C1′″), 61.3 (q, 3′″OMe), 57.4 (q, 2′″OMe), 40.3 (q, NMe2).
EXAMPLE 10 12,13-dihydro-12,13-dihydroxy-desmycosin-20-oxime (10)
Compound 9 (0.5 g, 0.62 mmole) was dissolved in ethanol (10 ml), pyridine (0.3 ml) and hydroxylamine hydrochloride (0.043 g, 0.62 mmole) were added and it was stirred in a nitrogen stream for 1 hour at room temperature. To the reaction mixture water (10 ml) was added and it was alkalized to a pH-value of 9 and evaporated to ⅓ of its volume. An extraction with chloroform at pH 5.5 (5 ml) and pH 9.0 (2×5 ml) was performed. The combined extracts (pH 9) were evaporated to a dry residue.
Obtained: 0.28 g (55%) Rf(E1) 0.35, MH+821; UV (EtOH) λmax 230 nm, log ε 3.67; 1H-NMR (DMSO-d6) δ ppm 10.37 (1H, s, 20-NOH), dissapears by agitation with D2O, 1H-NMR (CDCl3) δ ppm 6.81 (1H, d, H-11), 6.39 (1H, d, H-10), 4.52 (1H, d, 1′″), 4.33 (1H, d, 1′), 3.61 (3H, s, 3′″OMe), 3.45 (3H, s, 2′″OMe), 2.50 (6H, s, NMe2); 13C-NMR (CDCl3) δ ppm 203.2 (s, C-9), 172.9 (s, C-1), 151.5 (d, C-20), 148.8 (d, C-11), 123.8 (d, C-10), 104.7 (d, C-1′), 99.6 (d, C1′″), 61.3 (q, 3′″OMe), 57.4 (q, 2′″OMe), 40.3 (q, NMe2).

Claims (23)

What is claimed is:
1. 12,13-dihydroxy derivative of tylosin of the formula (I)
Figure US06211348-20010403-C00004
wherein
R represents O, R1 represents CHO, CH═NOH or CH(OCH3)2, R2 represents H or mycarosyl, R3 represents N(CH3)2 or NO(CH3)2, and - - - line represents a single or a double bond, with the proviso that R3 represents N(CH3)2 when - - - line represents a single bond; or
wherein
R represents NOH, R1 represents CHO or CH(OCH3)2, R2 represents H or mycarosyl, R3 represents N(CH3)2 or NO(CH3)2, and - - - line represents a single or a double bond, with the proviso that R3 represents N(CH3)2 when - - - line represents a single bond.
2. A tylosin derivative according to claim 1, wherein R represents O, R1 represents CH(OCH3)2, R2 represents H, R3 represents NO(CH3)2, and - - - line represents a double bond.
3. The tylosin derivative according to claim 1, wherein R represents O, R1 represents CH(OCH3)2, R2 represents mycarosyl, R3 represents NO(CH3)2, and - - - line represents a double bond.
4. The tylosin derivative according to claim 1, wherein R represents NOH, R1 represents CH(OCH3)2, R2 represents H, R3 represents NO(CH3)2, and - - - line represents a double bond.
5. The tylosin derivative according to claim 1, wherein R represents O, R1 represents CH(OCH3)2, R2 represents H, R3 represents N(CH3)2, and - - - line represents a double bond.
6. The tylosin derivative according to claim 1, wherein R represents O, R1 represents CH(OCH3)2, R2 represents H, R3 represents N(CH3)2, and - - - line represents a single bond.
7. The tylosin derivative according to claim 1, wherein R represents NOH, R1 represents CH(OCH3)2, R2 represents H, R3 represents N(CH3)2, and - - - line represents a single bond.
8. The tylosin derivative according to claim 1, wherein R represents NOH, R1 represents CH(OCH3)2, R2 represents H, R3 represents N(CH3)2, and - - - line represents a double bond.
9. The tylosin derivative according to claim 1, wherein R represents NOH, R1 represents CHO, R2 represents H, R3 represents N(CH3)2, and - - - line represents a double bond.
10. The tylosin derivative according to claim 1, wherein R represents O, R1 represents CHO, R2 represents H, R3 represents N(CH3)2, and - - - line represents a double bond.
11. The tylosin derivative according to claim 1, wherein R represents O, R1 represents CH═NOH, R2 represents H, R3 represents N(CH3)2, and - - - line represents a double bond.
12. A process for the preparation of a 12,13-dihydroxy tylosin derivative of the formula (I):
Figure US06211348-20010403-C00005
wherein
R represents O, R1 represents CHO, CH═NOH or CH(OCH3)2, R2 represents H or mycarosyl, R3 represents N(CH3)2 or NO(CH3)2 and - - - line represents a single or a double bond, with the proviso that R3 represents N(CH3)2 when - - - line represents a single bond; or
wherein
R represents NOH, R1 represents CHO or CH(OCH3)2, R2 represents H or mycarosyl, R3 represents N(CH3)2 or NO(CH3)2 and - - - line represents a single or a double bond, with the proviso that R3 represents N(CH3)2 when - - - line represents a single bond, wherein a compound of the formula (II):
Figure US06211348-20010403-C00006
wherein R represents H or mycarosyl, is subjected to an oxidation reaction, yielding a tylosin derivative having the formula I, wherein R represents O, R1 represents CH(OCH3)2, R2 represents H or mycarosyl, R3 represents NO(CH3)2, and - - - line represents a double bond, said tylosin derivative is optionally subjected:
A/ to a reduction of N-oxide; or optionally
B/ to a reduction of N-oxide and C10-C11 double bond; or optionally
C/ to an oximation reaction; or optionally
a compound of formula (I), wherein R represents NOH, R1 represents CH(OCH3)2, R2 represents H or mycarosyl, R3 represents NO(CH3)2, and - - - line represents a double bond, is subjected to a reduction of N-oxide; or optionally
to a reduction of N-oxide and C10-C11 double bond by catalytic hydrogenation;
or optionally
a compound of the formula (I), wherein R represents O, R1 represents CH(OCH3)2, R2 represents H or mycarosyl, R3 represents N(CH3)2, and - - - line represents a single or a double bond, is subjected to an oximation reaction; or optionally
a compound of formula (I), wherein R represents NOH, R1 represents CH(OCH3)2, R2 represents H or mycarosyl, R3 represents N(CH3)2, and - - - line represents a single or a double bond, subjected to hydrolysis.
13. A process according to claim 12, wherein said oxidation is performed with 3 to 8 equivalents of m-chloroperbenzoic acid in a halogenated hydrocarbon.
14. A process according to claim 13, wherein said reduction of N-oxide is performed with Zn-powder in a mixture of a lower C1-C3 aliphatic alcohol and water (1:2) under the addition of 3 to 5% w/v of ammonium chloride at a pH-value of 2 to 7.
15. A process according to claim 12, wherein said reduction of N-oxide and C10-C11 double bond is performed by catalytic hydrogenation in an organic solvent in the presence of 2 to 5% w/v of palladium on charcoal at a hydrogen pressure of 0.2 to 0.5 MPa at room temperature for from about 5 to about 8 hours.
16. A process according to claim 12, wherein said reduction of N-oxide and C10-C11 double bond is performed by electrochemical reduction in an electrochemical cell having separate anode and cathode compartments, wherein a Hg-basin is used as a working electrode (cathode), graphite is used as a counter electrode and a saturated calomel electrode is used as a reference electrode and wherein the pH is maintained at about 5.4 by a phosphate buffer at a constant potential of −1.4 V towards the saturated calomel electrode at room temperature within 40 minutes and a charge waste of 80 C.
17. A process according to claim 12, wherein said oximation is performed with about 1 to 8 equivalents of hydroxylamine hydrochloride in a pyridine or lower C1-C3 aliphatic alcohol under the addition of a base in a nitrogen stream at room temperature or at reflux temperature for about 1 to 10 hours.
18. A process according to claim 12, wherein said hydrolysis is performed in a mixture of acetonitrile and 0.2 N HCl (2:1) or of acetonitrile and 1% aqueous solution of trifluoroacetic acid (1:2) at room temperature for about 2 hours.
19. The process according to claim 13, wherein said halogenated hydrocarbon is methylene chloride and wherein said process is performed for from about 6 to about 20 hours at approximately room temperature.
20. The process according to claim 14, wherein said pH is from about 5.0 to about 5.5 and wherein said process is performed for from about 3 to about 6 hours at approximately room temperature.
21. The process according to claim 15, wherein said organic solvent is lower C1-C3-aliphatic alcohol.
22. The process according to claim 17, wherein said base is selected from the group consisting of pyridine and Na2CO3.
23. The process according to claim 18, wherein said hydrolysis is performed in a 1:2 mixture of acetonitrile and 1% aqueous solution of trifluoroacetic acid.
US09/393,322 1998-09-10 1999-09-10 Hydroxy derivatives of tylosin and process for their preparation Expired - Fee Related US6211348B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HR980496A HRP980496B1 (en) 1998-09-10 1998-09-10 New thilozine hydroxy derivatives and a process for the preparation thereof
HRP980496A 1998-09-10

Publications (1)

Publication Number Publication Date
US6211348B1 true US6211348B1 (en) 2001-04-03

Family

ID=10946806

Family Applications (1)

Application Number Title Priority Date Filing Date
US09/393,322 Expired - Fee Related US6211348B1 (en) 1998-09-10 1999-09-10 Hydroxy derivatives of tylosin and process for their preparation

Country Status (19)

Country Link
US (1) US6211348B1 (en)
EP (1) EP0985679B8 (en)
JP (1) JP2000086691A (en)
CN (1) CN1150202C (en)
AT (1) ATE238331T1 (en)
BG (1) BG64561B1 (en)
CA (1) CA2281496C (en)
CZ (1) CZ294935B6 (en)
DE (1) DE69907101T2 (en)
DK (1) DK0985679T3 (en)
ES (1) ES2198102T3 (en)
HR (1) HRP980496B1 (en)
HU (1) HUP9903063A2 (en)
NO (1) NO312839B1 (en)
PL (1) PL195483B1 (en)
RU (1) RU2220149C2 (en)
SI (1) SI0985679T1 (en)
SK (1) SK284841B6 (en)
UA (1) UA66355C2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006073172A1 (en) * 2005-01-07 2006-07-13 Meiji Seika Kaisha, Ltd. 12-oxy-13-amino-containing 16-membered cyclic macrolide derivative and process for producing the same

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7247617B2 (en) 2004-07-13 2007-07-24 Kosan Biosciences Incorporated Sixteen-member macrolide antiinfective agents
FR2891835B1 (en) * 2005-10-11 2007-12-14 Alchimer Sa PROCESS FOR MODIFYING SURFACES OF POLYMERS, IN PARTICULAR HYDROXYLATION OF POLYMER SURFACES, AND PRODUCTS SUCH AS OBTAINED
CN117510561B (en) * 2023-11-30 2024-04-02 中国农业科学院饲料研究所 Tylosin derivative and preparation method and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688924A (en) * 1995-08-14 1997-11-18 Pliva Farmaceutska, Kemijska, Prehrambena I Kozmeticka Industrija, D.D. Derivatives of 12,13-Epoxy-tylosin and processes of manufacture thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BG32649A1 (en) * 1981-03-26 1982-09-15 Kirov Method for obtaining of antibiotic tilozine
AU551142B2 (en) * 1981-07-09 1986-04-17 Zaidan Hojin Biseibutsu Kagaku Kenkyukai Tylosin derivatives
US4454314A (en) * 1982-08-02 1984-06-12 Pfizer Inc. Antibacterial mycaminosyl tylonolide and related macrolide derivatives
ATE60025T1 (en) * 1986-10-22 1991-02-15 Ferag Ag METHOD AND DEVICE FOR TAKING FOLDED PRINTING PRODUCTS FROM PRINTING MACHINES.
SI8710674B (en) * 1987-04-14 1998-06-30 Pliva Process for preparation of 10,11,12,13-tetrahydro derivatives of tylosin
DE4200145A1 (en) * 1992-01-07 1993-07-08 Kali Chemie Pharma Gmbh 7,10-EPOXY-OXACYCLODODANE DERIVATIVES, METHODS AND INTERMEDIATE PRODUCTS FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THESE COMPOUNDS
JP3063943B2 (en) * 1992-02-26 2000-07-12 明治製菓株式会社 Novel 16-membered ring macrolide derivatives having sustained antibacterial activity in plasma, intermediates for synthesizing the same and methods for producing them
HRP960509A2 (en) * 1996-10-30 1998-06-30 Pliva Pharm & Chem Works Novel polyhydro tylosin derivatives and a process for the preparation thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688924A (en) * 1995-08-14 1997-11-18 Pliva Farmaceutska, Kemijska, Prehrambena I Kozmeticka Industrija, D.D. Derivatives of 12,13-Epoxy-tylosin and processes of manufacture thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006073172A1 (en) * 2005-01-07 2006-07-13 Meiji Seika Kaisha, Ltd. 12-oxy-13-amino-containing 16-membered cyclic macrolide derivative and process for producing the same

Also Published As

Publication number Publication date
HRP980496B1 (en) 2007-03-31
BG103726A (en) 2000-12-29
SI0985679T1 (en) 2003-10-31
UA66355C2 (en) 2004-05-17
CN1150202C (en) 2004-05-19
NO312839B1 (en) 2002-07-08
SK284841B6 (en) 2005-12-01
EP0985679B1 (en) 2003-04-23
CN1250054A (en) 2000-04-12
BG64561B1 (en) 2005-07-29
EP0985679B8 (en) 2003-09-03
HUP9903063A2 (en) 2000-03-28
NO994366D0 (en) 1999-09-09
PL335362A1 (en) 2000-03-13
CZ294935B6 (en) 2005-04-13
ATE238331T1 (en) 2003-05-15
CA2281496C (en) 2005-11-01
ES2198102T3 (en) 2004-01-16
HRP980496A2 (en) 2000-04-30
CZ315499A3 (en) 2000-04-12
CA2281496A1 (en) 2000-03-10
SK124199A3 (en) 2000-12-11
EP0985679A1 (en) 2000-03-15
JP2000086691A (en) 2000-03-28
DE69907101T2 (en) 2004-04-08
DE69907101D1 (en) 2003-05-28
PL195483B1 (en) 2007-09-28
NO994366L (en) 2000-03-13
DK0985679T3 (en) 2003-08-11
RU2220149C2 (en) 2003-12-27

Similar Documents

Publication Publication Date Title
EP0109253B1 (en) Epimeric azahomoerythromycin a derivative and intermediates therefor
EP0287082B1 (en) Derivatives of tylosin and 10,11,12,13-tetrahydro tylosin, methods of manufacture thereof and their use in pharmaceuticals and in the manufacture thereof
US6211348B1 (en) Hydroxy derivatives of tylosin and process for their preparation
EP0410433A2 (en) Tylosin derivatives
US5922684A (en) Polyhydro derivatives of tylosine and process for their preparation
US5688924A (en) Derivatives of 12,13-Epoxy-tylosin and processes of manufacture thereof
CZ20014362A3 (en) 4'-demycarosyl-8a-aza-8a-homotylosines and process for preparing thereof
US6504035B1 (en) 3-deoxy-desmycosin derivatives and process for their preparation
EP0448035A1 (en) Oleandomycin oximes, preparation and use thereof

Legal Events

Date Code Title Description
AS Assignment

Owner name: PLIVA, FARMACEUTSKA INDUSTRIJA, DIONICKO DRUSTVO,

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:NARANDJA, AMALIJA;LOPOTAR, NEVENKA;MANDIC, ZORAN;REEL/FRAME:010303/0867

Effective date: 19990921

FPAY Fee payment

Year of fee payment: 4

AS Assignment

Owner name: PLIVA-ISTRAZIVACKI INSTITUT D.O.O., CROATIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PLIVA D.D.;REEL/FRAME:015621/0250

Effective date: 20041228

FPAY Fee payment

Year of fee payment: 8

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20130403